ENDRA Life Sciences granted extension to regain compliance with Nasdaq continued listing requirements

ENDRA Life Sciences ( NASDAQ: NDRA ) on Wednesday said it was notified by Nasdaq that the Nasdaq Hearings Panel has granted the company’s request for an extension through November 20 to evidence compliance with the $1.00 bid price requirement for continued listing. NDRA +11.

11% after hours to $0.455. Source: Press Release More on Endra Life Sciences Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings data for Endra Life Sciences Financial information for Endra Life Sciences.